Compare EQH & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQH | NBIX |
|---|---|---|
| Founded | 1859 | 1992 |
| Country | United States | United States |
| Employees | 8000 | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 13.2B |
| IPO Year | N/A | 1996 |
| Metric | EQH | NBIX |
|---|---|---|
| Price | $43.80 | $166.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | $56.82 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 4.0M | 1.1M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $43.13 | $24.73 |
| Revenue Next Year | $7.45 | $13.14 |
| P/E Ratio | ★ N/A | $85.87 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $35.20 | $122.14 |
| 52 Week High | $56.61 | $169.57 |
| Indicator | EQH | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 62.32 |
| Support Level | $42.30 | $153.96 |
| Resistance Level | $46.93 | $169.57 |
| Average True Range (ATR) | 1.15 | 4.79 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 51.02 | 80.36 |
Equitable Holdings Inc is a financial services company providing retirement, asset management, and wealth management solutions for individual and institutional clients, operating through three segments. The Retirement segment generates the majority of revenue and offers annuities, retirement savings plans, institutional savings products, and includes the spread lending business. The Asset Management segment provides diversified investment management and related services globally through Institutional, Retail, and Private Wealth channels and reflects the business of AB. The Wealth Management segment offers advisory accounts, financial planning and advice, life insurance, and annuity products. Revenues are earned predominantly from fee income, income from investments, and insurance premiums.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.